NCT02503657Phase 2Completed

Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis

Study sponsor: MediciNova

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2020-12-07Actual
Enrollment · participants15Actual
Source updated2026-01-23Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from baseline of FVC (forced vital capacity) at 26 weeks. After: Measure: Absolute Change From Baseline in Forced Vital Capacity for 26 Weeks Measure: Percent Change in Forced Vital Capacity From Baseline to Week 26 Measure: Absolute Change From Baseline in Forced Vital Capacity (% Predicted) Measure: Relative Change From Baseline in Percent Predicted Forced Vital Capacity From Baseline to Week 26 Measure: Semiannual Rate of Decline of Disease Activity Based on Forced Vital Capacity.

Check registry source